Owkin Stock

owkin.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $279.77MM

Owkin is an AI biotech company using federated learning to connect biopharma companies and medical partners. Owkin's technology unlocks insights from siloed datasets that allow for the development of precise medical approaches to the treatment of disease. Owkin was founded in 2016 by Dr. Thomas Clozel and Dr. Gilles Wainrib and is headquartered in New York, NY.

Register for Details

For more details on financing and valuation for Owkin, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Owkin.

Register Today

Owkin investors also invested in these private companies


Management Team

Hubert Chaperon
Chief Operating Officer
Darius Meadon
Chief Marketing Officer
Gilles Wainrib Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Meriem Sefta Ph.D
Chief Diagnostics Officer & Chief Data and Clinical Solution Officer
Alban Sablière
Chief Business Officer
Jean-Philippe Vert
Chief Research and Development Officer
Jean-Frédéric Petit-Nivard
Chief Commercial Officer
Thomas Clozel MD
Co-Founder, Chief Executive Officer & Board Member
Mathieu Galtier Ph.D
Chief Data and Platform Officer
Vassili Soumelis
Chief Medical Officer
Andreas Emmenegger
Chief Financial Officer
Anna Huyghues-Despointes
Chief Corporate Development Officer
David Cahane
Chief Solutions Officer
Mariabrisa Olivares
Chief People Officer
Leo Cunningham
Chief Information Security Officer

Board Members

Jacky Abitbol
Cathay Innovation
Laurent Higueret, PharmD
Alex Pasteur
F-Prime Capital
Bruno Raillard
FRST Capital
Nicole Junkermann
NJF Holdings

Other companies like Owkin in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Pigment, Payfit and Owkin-backer Frst has closed €72m of third fund
Paris-based VC firm Frst has closed €72m of its third fund, with investors including the European Investment Fund, Bpifrance, Axa Venture Partners, Isomer and Mubadala. The firm plans to invest the capital over four years into 30 seed-stage companies across various sectors, with investments ranging between €1m-3m. Frst aims to close the fund at €100m and is seeking more sovereign wealth funds, fund-of-funds and asset managers to invest.
Owkin invests $50M in spatial omics project that will 'revolutionize cancer research'
Owkin, an AI biotech company, has invested $50 million in a project using spatial omics to revolutionize cancer research. The project, named MOSAIC, will be conducted in collaboration with Nanostring Technologies and several leading cancer research institutions. Spatial omics allows researchers to examine tumors at near single-cell resolution, providing a detailed map of molecular interactions. The project aims to unlock the next wave of treatments for difficult-to-treat cancers.
MOSAIC Brings Big Guns to Spatial Genomics in Oncology
The Multi Omic Spatial Atlas in Cancer (MOSAIC) project, a collaboration involving several leading cancer research institutes, AI biotech pioneer Owkin, and spatial omics specialists NanoString, will mine 7,000 patient tumor samples for new biomarkers and therapeutics. Owkin is investing $50 million in the project, which aims to leverage spatial omics and AI to revolutionize oncology research and treatment.
Updated on: Sep 28, 2023